Lupin launches generic Seroquel XR tablets in US

23 Aug 2017 Evaluate

Pharma Major Lupin has launched its Quetiapine Fumarate Extended?Release Tablets, 50 mg, 150 mg, 200 mg, 300 mg and 400 mg having received an approval from the United States Food and Drug Administration (FDA) earlier. Seroquel XR Tablets had US sales of $1.1 billion as per IMS MAT June 2017.

Lupin’s Quetiapine Fumarate Extended?Release Tablets, 50 mg, 150 mg, 200 mg, 300 mg and 400 mg are the AB rated generic equivalent of AstraZeneca Pharmaceuticals LP’s Seroquel XR Tablets, 50 mg, 150 mg, 200 mg, 300 mg and 400 mg. It is indicated for the treatment of schizophrenia; acute manic or mixed episodes in bipolar I disorder alone or as an adjunct to lithium or divalproex; acute depressive episodes in bipolar disorder; maintenance treatment of bipolar I disorder, as an adjunct to lithium or divalproex and as an adjunctive therapy to antidepressants for the treatment of major depressive disorder.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2089.65 -0.50 (-0.02%)
16-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1782.80
Dr. Reddys Lab 1279.00
Cipla 1500.00
Zydus Lifesciences 913.90
Lupin 2089.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×